Clinical Trial Update: Observational Study on the Prophylactic Use of Curosurf in Neonatal Respiratory Distress Syndrome (RDS)

View source ↗

Summary

Completion of an observational study evaluating the prophylactic use of Curosurf (poractant alfa) in newborn respiratory distress syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome Newborn

Drugs mentioned

• Curosurf (poractant alfa)

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Respiratory Distress Syndrome, Newborn | Status: COMPLETED